2. Neuronal Signaling Stem Cell/Wnt
  3. Notch
  4. Tarextumab

Tarextumab  (Synonyms: OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody)

Cat. No.: HY-P99320 Purity: 96.80%
COA
SDS
Technical Support

Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer.

For research use only. We do not sell to patients.

CAS No. : 1359940-55-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tarextumab Featured Recommendations:

Tarextumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer[1][2].

Isotype

Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

NOTCH3
In Vitro

Tarextumab inhibits human Notch2 and Notch3 signaling activity (reduces RLU values) without affecting Notch1 in HeLa cells using a Notch-responsive luciferase reporter assay[1].
Tarextumab downregulates mRNA expression of human Notch2, Notch3, HES1, NANOG, and OCT4, and reverses Gemcitabine (HY-17026)-induced upregulation of EMT-related genes (CDH2, VIM, FN1) in OMP-PN17 pancreatic tumor cells[1].
Tarextumab reduces protein levels of Notch3 extracellular domain (ECD) and active intracellular domain (ICD) in OMP-PN17 pancreatic tumor cells, and decreases the number of cells with high Notch3 ECD staining[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tarextumab Related Antibodies
In Vivo

Tarextumab (40 mg/kg, i.p., every other week) combined with Gemcitabine (HY-17026) inhibits tumor growth and induces tumor regression in pancreatic cancer PDX models in NOD/SCID mice[1].
Tarextumab (40 mg/kg, i.p., once weekly, 4 weeks) does not induce marked tumor growth inhibition in MDA-MB-468 and HCC70 TNBC cell line-derived xenograft models in BALB/c nude mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human pancreatic cancer cells (from PDX models including OMP-PN4, OMP-PN8, OMP-PN17) were subcutaneously implanted into NOD/SCID mice[1]
Dosage: 40 mg/kg combined with Gemcitabine (HY-17026)
Administration: i.p., every other week
Result: Achieved enhanced antitumor efficacy.
Showed striking tumor regression.
Reduced cancer stem cell (CSC) frequency.
Delayed tumor recurrence.
Decreased tumor cell proliferation.
Increased pericyte maturation (enhanced desmin-positive pericyte association with CD31-positive endothelial cells) and tumor vascular perfusion and reduced intratumoral hypoxia.
Animal Model: Triple-negative breast cancer (TNBC) cells (from cell lines including MDA-MB-468, HCC70) were subcutaneously implanted into BALB/c nude mice[2]
Dosage: 40 mg/kg
Administration: i.p., once weekly, 4 weeks
Result: Reduced tumor-initiating cell (TIC) frequency.
Clinical Trial
Gene ID

4854  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

142.94 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tarextumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG2 kappa
Biological Activity
  • Immobilized NOTCH2 Protein (His Tag), Human can bind Tarextumab. The EC50 for this effect is 1.22 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tarextumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tarextumab1359940-55-8OMP 59R5 Anti-Human NOTCH2 Recombinant AntibodyNotchNotch2Notch3cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tarextumab
Cat. No.:
HY-P99320
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.